Around 20% of patients with advanced prostate cancer present germline or tumour mutations in HRR-related genes, the most common being BRCA2. The recent approvals of PARP inhibitors represent the first molecular guided pharmaceutical agents for men with prostate cancer. This webinar series aims to highlight the recent developments on PARP inhibitors in prostate cancer.
Click here to watch part 1 of this series.